Teladoc Health, Inc. (NYSE:TDOC) Given Average Rating of “Hold” by Brokerages

Teladoc Health, Inc. (NYSE:TDOC) has been assigned an average rating of “Hold” from the eighteen analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and five have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $9.50.

Several equities analysts have commented on the stock. Evercore ISI decreased their price objective on shares of Teladoc Health from $9.00 to $8.00 and set an “in-line” rating for the company in a research note on Thursday, October 30th. Zacks Research downgraded Teladoc Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Bank of America reduced their price objective on Teladoc Health from $9.00 to $8.00 and set a “neutral” rating for the company in a research note on Tuesday, November 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Teladoc Health in a report on Monday, December 29th. Finally, Citigroup cut their target price on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Friday, January 9th.

Teladoc Health Price Performance

TDOC opened at $6.26 on Monday. The company has a current ratio of 2.70, a quick ratio of 2.60 and a debt-to-equity ratio of 0.71. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -4.89 and a beta of 2.04. The stock’s 50-day moving average price is $7.26 and its 200 day moving average price is $7.75. Teladoc Health has a 12-month low of $6.26 and a 12-month high of $15.21.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, October 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. The company had revenue of $626.44 million for the quarter, compared to analyst estimates of $625.66 million. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.Teladoc Health’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.19) EPS. Teladoc Health has set its Q4 2025 guidance at -0.250–0.100 EPS. As a group, sell-side analysts expect that Teladoc Health will post -1.16 earnings per share for the current year.

Insider Buying and Selling

In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total transaction of $130,762.94. Following the completion of the transaction, the chief executive officer owned 201,036 shares in the company, valued at approximately $1,533,904.68. This represents a 7.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Fernando M. Rodrigues sold 4,209 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $7.48, for a total transaction of $31,483.32. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 33,288 shares of company stock valued at $251,684. Company insiders own 0.58% of the company’s stock.

Institutional Trading of Teladoc Health

Hedge funds have recently modified their holdings of the business. AFG Fiduciary Services Limited Partnership purchased a new position in shares of Teladoc Health in the 4th quarter valued at about $92,000. IFP Advisors Inc increased its holdings in Teladoc Health by 412.1% in the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after buying an additional 3,210 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new position in Teladoc Health in the third quarter valued at about $145,000. CANADA LIFE ASSURANCE Co lifted its position in shares of Teladoc Health by 8.0% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 60,231 shares of the health services provider’s stock valued at $494,000 after acquiring an additional 4,458 shares during the period. Finally, Verition Fund Management LLC boosted its stake in shares of Teladoc Health by 152.0% during the 3rd quarter. Verition Fund Management LLC now owns 218,572 shares of the health services provider’s stock worth $1,690,000 after acquiring an additional 131,833 shares in the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.